Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase

Virology Journal

Volumn 5, Issue , 2008, Pages

  Paskaleva, Elena E ^a   Lin, Xudong ^a   Duus, Karen ^a   McSharry, James J ^b   Veille, Jean Claude L ^a   Thornber, Carol ^c   Liu, Yanze ^d   Lee, David Yu Wei ^d   Canki, Mario ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; RECEPTOR; RNA DIRECTED DNA POLYMERASE; SP 4 2; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL PRODUCT; CD4 ANTIGEN; ENZYME INHIBITOR; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS RECEPTOR;

ALGA; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; ENZYME INHIBITION; FRACTIONATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; NONHUMAN; SARGASSUM FUSIFORME; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; SARGASSUM; VIROLOGY; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1; SARGASSUM FUSIFORME;

ANTI-HIV AGENTS; ANTIGENS, CD4; BIOLOGICAL PRODUCTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, VIRUS; SARGASSUM; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 40849116271     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-8     Document Type: Article

References (20)

1. Phylogenetic relationships within the genus Sargassum (Fucales, Phaeophyceae), inferred frm it ITS nrDNA, with an emphasis on the taxonomic revision of the genus. V Stieger T Horiguchi T Yoshida AW Coleman M Masuda, Phyc Res 2003 51 1 10 10.1111/j.1440-1835.2003.tb00164.x
2. Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme. EE Paskaleva X Lin W Li R Cotter MT Klein E Roberge EK Yu BW Clark JC Veille Y Liu DY Lee M Canki, AIDS Res Ther 2006 3 15 16725040 10.1186/1742-6405-3-15
3. An antivirally active sulfated polysaccharide from Sargassum horneri (TURNER) C. AGARDH. T Hoshino T Hayashi K Hayashi J Hamada JB Lee U Sankawa, Biol Pharm Bull 1998 21 730 734 9703258
4. Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. M Witvrouw E De Clercq, Gen Pharmacol 1997 29 497 511 10.1016/S0306-3623(96)00563-0 9352294
5. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. M Cavrois C De Noronha WC Greene, Nat Biotechnol 2002 20 1151 1154 10.1038/nbt745 12355096
6. Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. M Cavrois J Neidleman M Bigos WC Greene, Methods Mol Biol 2004 263 333 344 14976375
7. Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. M Canki JNF Thai W Chao A Ghorpade MJ Potash DJ Volsky, J Virol 2001 75 7925 7933 11483737 10.1128/JVI.75.17.7925-7933.2001
8. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. JA Turpin, Expert Opin Investig Drugs 2002 11 1077 1097 10.1517/13543784.11.8.1077 12150703
9. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. M Moulard H Lortat-Jacob I Mondor G Roca R Wyatt J Sodroski L Zhao W Olson PD Kwong QJ Sattentau, J Virol 2000 74 1948 1960 10644368 10.1128/JVI.74.4.1948-1960.2000
10. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. M Baba R Snoeck R Pauwels E de Clercq, Antimicrob Agents Chemother 1988 32 1742 1745 2472775
11. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. E Aguilar-Cordova J Chinen L Donehower DE Lewis JW Belmont, AIDS Res Hum Retroviruses 1994 10 295 301 8018390
12. Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines. SD Smith M Shatsky PS Cohen R Warnke MP Link BE Gladen, Cancer Res 1984 44 5657 5660 6437672
13. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. A Morner A Bjorndal J Albert VN Kewalramani DR Littman R Inoue R Thorstensson EM Fenyo E Bjorling, J Virol 1999 73 2343 2349 9971817
14. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. A Adachi HE Gendelman S koening T Folks R Willey A Rabson M Martin, Journal of Virology 1986 59 284 291 3016298
15. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. K Toohey K Wehrly J Nishio S Perryman B Chesebro, Virology 1995 213 70 79 10.1006/viro.1995.1547 7483281
16. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J He S Choe R Walker P Di Marzio DO Morgan NR Landau, J Virol 1995 69 6705 6711 7474080
17. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. RI Connor BK Chen S Choe NR Landau, Virol 1995 206 935 944 10.1006/viro.1995.1016
18. Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control. SR Bartz ME Rogel M Emerman, J Virol 1996 70 2324 2331 8642659
19. Current protocols in molecular biology. MF Ausubel R Brent ER Kingston DD Moore GJ Seidman AJ Smith K Struhl, New York, N.Y., John Wiley & Sons, Inc. 1995
20. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Kimpton M Emerman, J Virol 1992 66 2232 2239 1548759